Mylan
Search results
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. [2]
Viatris is a global pharmaceutical company that believes in healthcare not as it is, but as it should be. Learn about our story, explore our products and browse career opportunities.
Viatris is a unique global healthcare company focused on a wide variety of therapeutic areas, empowering people worldwide by expanding their access to a broad range of trusted, quality medications, regardless of geography or circumstance.
With one of our global centers located in Hyderabad, we have a strong presence in India, where our development and manufacturing facilities support the production of high-quality medicines for global markets.
Viatris produces high quality medicines across a broad range of therapeutic areas. Explore our brands, generics, biosimilars, over-the-counter products and API.
It’s a place where you can learn, grow and make an impact in the world. If you’re inspired by our bold mission to empower people worldwide to live healthier at every stage of life, explore global opportunities to join our team of dedicated individuals. Find your next role.
Viatris brings quality medicines to patients when and where they need them through our Global Healthcare Gateway. Learn about our mission and global impact and reach.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically...
Nov 12, 2019 · Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.
The Investor Relations website contains information about Viatris's business for stockholders, potential investors, and financial analysts.
